Molecular Cancer Therapeutics

Basic Information

Brief Name: MOL CANCER THER
Impact Factor: 5.3
ISSN: 1535-7163
Research Field: MEDICAL
h-index: 157
Self-citation Rate: 2.6%
Articles per Year: 116

SCI Index Status: Science Citation Index Expanded
Journal Introduction:

Molecular Cancer Therapeutics publishes translational research studies focused on the discovery and preclinical development of therapeutic agents for oncology. To reflect the evolving field of therapeutics, the journal’s interest extends to all selective drugs including small molecule inhibitors, antibody-drug conjugates, antibody cytokine fusions, bispecific antibodies, cell therapies, gene therapies, radio-immunotherapeutics, vaccines, viral therapies, and other experimental approaches in oncology. Specific areas of interest are the disclosure of translational investigations of novel drug therapies, preclinical studies of approved therapeutics (including their combination with radiation therapy), mechanisms of action, mitigation of resistance, biomarkers of response, novel models and technology, and applications of big data in drug discovery.

CiteScore

CiteScore
11.2
SJR
2.27
SNIP
1.016
Subject Rank Percentile
MedicineOncology
48 / 404 88%

Journal Statistics

Monthly
Issues/Year
Review Cycle
CC BY-NC-ND: 6000 CC BY: 7000
Article Processing Fee

Submission Information

Related Articles

Secondary structure of proteins analyzed ex vivo in vascular wall in diabetic animals using FT-IR spectroscopy

Katarzyna Majzner, Andrzej Fedorowicz

2013-09-23 Paper

DOI: 10.1039/C3AN00455D

An analytical quality solid-state composite reference electrode

Zekra Mousavi, Kim Granholm, Tomasz Sokalski

2013-06-24 Paper

DOI: 10.1039/C3AN00852E

Development of a high-throughput assay for measuring lipase activity using natural triacylglycerols coated on microtiter plates

Carole Serveau-Avesque, Robert Verger, Jorge A. Rodriguez, Abdelkarim Abousalham

2013-06-25 Paper

DOI: 10.1039/C3AN36699E

Discrimination of circulating tumor cells of breast cancer and colorectal cancer from normal human mononuclear cells using Raman spectroscopy

Václav Ranc, Josef Srovnal, Libor Kvítek, Marian Hajduch

2013-07-24 Paper

DOI: 10.1039/C3AN00855J

Peroxide induced ultra-weak chemiluminescence and its application in analytical chemistry

Hui Chen, Jin-Ming Lin

2013-06-12 Tutorial Review

DOI: 10.1039/C3AN00910F

A compact high resolution ion mobility spectrometer for fast trace gas analysis

Ansgar T. Kirk, Maria Allers, Philipp Cochems, Jens Langejuergen, Stefan Zimmermann

2013-04-23 Paper

DOI: 10.1039/C3AN00231D

Silver colloidal pastes for dye analysis of reference and historical textile fibers using direct, extractionless, non-hydrolysis surface-enhanced Raman spectroscopy

Monica Gulmini, Anne-Isabelle Henry, Francesca Casadio, Lauren Chang, Lorenzo Appolonia, Richard P. Van Duyne, Nilam C. Shah

2013-07-26 Paper

DOI: 10.1039/C3AN00788J

On-chip screening for prostate cancer: an EIS microfluidic platform for contemporary detection of free and total PSA

Maria Serena Chiriacò, Elisabetta Primiceri, Alessandro Montanaro, Francesco de Feo, Lorenzo Leone, Ross Rinaldi, Giuseppe Maruccio

2013-06-26 Paper

DOI: 10.1039/C3AN00911D

Molecular Cancer Therapeutics

Recommended Suppliers

ChinaBTI (Chengdu) Biotechnology Co., Ltd.
ChinaJiangxi Tuoge Medicina Technology Co., Ltd.
ChinaChengdu Ali Li Chemical Industry Co., Ltd.
ChinaJiangxi Yongtai Chemical Co., Ltd.
ChinaShandong Provincial Fafen Chemical Co., Ltd.
ChinaLihang Rare Earth Industry Co., Ltd. Lianyungang City
ChinaJinan Jinyangshuo Chemical Co., Ltd.
VenezuelaRepresentaciones ALFIL C.A.
ChinaLanson Laboratory Equipment Co., Ltd
GermanyKendrion Kuhnke Automation GmbH
Disclaimer
This page provides academic journal information for reference and research purposes only. We are not affiliated with any journal publishers and do not handle publication submissions. For publication-related inquiries, please contact the respective journal publishers directly.
If you notice any inaccuracies in the information displayed, please contact us at [email protected]. We will promptly review and address your concerns.